Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.77 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.77 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.77 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.77 |
| ▸ | STK39 | Q9UEW8 | 11/20 | 0.70 |
| ▸ | PNLIP | P16233 | 1/20 | 0.69 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.66 |
| ▸ | PARG | Q86W56 | 3/20 | 0.64 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.60 |
| ▸ | CTSD | P07339 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29375129 | 1.00 | PTGS1 (0.77) | PTGS1TBXAS1MAPK1PTGS2MAPK14 | |
| SCHEMBL21570088 | 0.91 | STK39 (0.85) | PTGS1TBXAS1MAPK1PTGS2MAPK14 | |
| SCHEMBL11692717 | 0.89 | PTGS1 (0.71) | PTGS1TBXAS1MAPK1PTGS2MAPK14 | |
| SCHEMBL10457403 | 0.89 | PARG (0.71) | PTGS1TBXAS1MAPK1PTGS2MAPK14 | |
| SCHEMBL25413048 | 0.89 | PTGS1 (0.71) | PTGS1TBXAS1MAPK1PTGS2MAPK14 | |
| SCHEMBL9868077 | 0.89 | STK39 (0.77) | PTGS1TBXAS1MAPK1PTGS2MAPK14 | |
| 3,3',4',5-Tetrachlorosalicylanilide SCHEMBL29367227 | 0.87 | PTGS1 (1.00) | PTGS1TBXAS1MAPK1PTGS2MAPK14 | |
| 3,3',4',5-Tetrachlorosalicylanilide SCHEMBL168748 | 0.87 | PTGS1 (1.00) | PTGS1TBXAS1MAPK1PTGS2MAPK14 | |
| Hydrochloric Acid SCHEMBL11777767 | 0.87 | STK39 (0.75) | PTGS1TBXAS1MAPK1PTGS2MAPK14 | |
| SCHEMBL29211122 | 0.85 | P2RX1 (0.64) | PTGS1TBXAS1MAPK1PTGS2MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 225 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150056160-A1 | CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA | TEXAS PHARMACEUTICALS, INC. | 2015-02-26 | — | — | US | claimed |
| EP-2313026-A1 | ACTIVE DELIVERY SYSTEM FORMULATIONS | Castle Beach, L.L.C. (US) | 2011-04-27 | — | — | EP | claimed |
| US-20100040565-A1 | ACTIVE DELIVERY SYSTEMS FORMULATIONS | Castle Beach, LLC (US) | 2010-02-18 | — | — | US | claimed |
| WO-2010019680-A1 | ACTIVE DELIVERY SYSTEM FORMULATIONS | HOMOLA ANDREW M (US) | 2010-02-18 | — | — | WO | claimed |
| WO-2010008737-A2 | ANTIMICROBIAL FLUID HANDLING DEVICES AND METHODS OF MANUFACTURE | PELICAN GROUP HOLDINGS, INC. (US) | 2010-01-21 | — | — | WO | claimed |
| EP-1458419-B1 | ANTIMICROBIAL CONTACT LENS CASE | NOVARTIS AG (CH) | 2005-05-04 | — | — | EP | claimed |
| EP-1458419-A1 | ANTIMICROBIAL CONTACT LENS CASE | Novartis AG (CH) | 2004-09-22 | — | — | EP | claimed |
| EP-0805672-B1 | METHODS, COMPOSITIONS, AND DENTAL DELIVERY SYSTEMS FOR THE PROTECTION OF THE SURFACES OF TEETH | HOMOLA ANDREW M (US) | 2004-08-25 | — | — | EP | claimed |
| US-20030176530-A1 | Antimicrobial contact lens case | LINDLEY KAREN FRANCES (US) | 2003-09-18 | — | — | US | claimed |
| EP-1098641-A4 | CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA | ST JUDE PHARMACEUTICALS INC (US) | 2003-08-27 | — | — | EP | claimed |
| WO-2003049776-A1 | ANTIMICROBIAL CONTACT LENS CASE | NOVARTIS AG (CH) | 2003-06-19 | — | — | WO | claimed |
| EP-1098641-A1 | CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA | Texas Pharmaceuticals, Inc. (US) | 2001-05-16 | — | — | EP | claimed |
| WO-2000006143-A1 | CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA | TEXAS PHARMACEUTICALS, INC. (US) | 2000-02-10 | — | — | WO | claimed |
| US-5665333-A | Methods, compositions, and dental delivery systems for the protection of the surfaces of teeth | PROVSEAL LLC | 1997-09-09 | — | — | US | claimed |
| US-4022880-A | ZINC IONS, 3,4,5-TRIBROMO-SALICYLANILIDE, QUATERNARY AMMONIUM COMPOUNDS | LEVER BROTHERS COMPANY (US) | 1977-05-10 | — | — | US | claimed |
| EP-3528776-B1 | REDUCED-ETHANOL MOUTH RINSE FORMULATIONS | KENVUE BRANDS LLC (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4551195-A1 | CANNABINOID LIPID PREMIXTURE | Fertin Pharma A/S (DK) | 2025-05-14 | — | — | EP | disclosed |
| US-4022880-A | ZINC IONS, 3,4,5-TRIBROMO-SALICYLANILIDE, QUATERNARY AMMONIUM COMPOUNDS | LEVER BROTHERS COMPANY (US) | 1977-05-10 | — | — | US | disclosed |
| US-4010252-A | POLYQUATERNARY AMMONIUM COMPOUND, DEODORANTS | COLGATE-PALMOLIVE COMPANY (US) | 1977-03-01 | — | — | US | disclosed |
| US-3956510-A | NESTING, CYLINDERS, LOOPS | BEALL NELSON J | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100040565-A1 | ACTIVE DELIVERY SYSTEMS FORMULATIONS | LIPA, MMP7, CTSA | PTGS1 328/4885TBXAS1 388/4885MAPK1 4317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.